|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000175029 |
Summary for CTBP2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000175029 | Gene symbol | CTBP2 |
| Gene name | C-terminal binding protein 2 | |
| HGNC | 2495 | |
| Entrez ID | 1488 | |
| Gene type | protein_coding | |
| Synonyms | CTBP2|ribeye | |
| UniProtAcc | P56545 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CTBP2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CTBP2 | 2.32e+03 | 2.56e+00 | 3.20e-01 | 8.02e+00 | 1.05e-15 | 4.94e-14 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for CTBP2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CTBP2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KICH | cg05090351 | chr10:125162593 | CGI:chr10:125158655-125162758 | promoter | 5.55e-01 | 6.91e-01 | -2.22e+00 | 2.62e-02 | 4.10e-02 | -1.36e-01 |
| CHOL | cg23000734 | chr10:125162254 | CGI:chr10:125158655-125162758 | promoter | 4.02e-01 | 2.29e-01 | 3.47e+00 | 5.20e-04 | 2.21e-03 | 1.73e-01 |
| CHOL | cg05090351 | chr10:125162593 | CGI:chr10:125158655-125162758 | promoter | 8.15e-01 | 6.90e-01 | 2.52e+00 | 1.19e-02 | 2.40e-02 | 1.25e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| THCA | cg23000734 | chr10:125162254 | CGI:chr10:125158655-125162758 | promoter | 5.20e-01 | 4.12e-01 | 2.69e+00 | 7.16e-03 | 1.30e-02 | 1.08e-01 |
| THCA | cg05090351 | chr10:125162593 | CGI:chr10:125158655-125162758 | promoter | 7.67e-01 | 6.40e-01 | 3.16e+00 | 1.59e-03 | 4.38e-03 | 1.27e-01 |
| LIHC | cg03862225 | chr10:125161885 | CGI:chr10:125158655-125162758 | promoter | 1.72e-01 | 3.38e-02 | 2.09e+00 | 3.65e-02 | 3.80e-02 | 1.39e-01 |
| CHOL | cg05090351 | chr10:125162593 | CGI:chr10:125158655-125162758 | promoter | 6.90e-01 | 4.90e-01 | 2.58e+00 | 9.87e-03 | 2.15e-02 | 2.00e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg05090351 | chr10:125162593 | CGI:chr10:125158655-125162758 | promoter | 5.11e-01 | 7.67e-01 | -1.38e+01 | 3.49e-43 | 6.80e-41 | -2.56e-01 |
| HNSC | cg05090351 | chr10:125162593 | CGI:chr10:125158655-125162758 | promoter | 7.27e-01 | 5.58e-01 | 2.67e+00 | 7.60e-03 | 1.62e-02 | 1.69e-01 |
| LIHC | cg23000734 | chr10:125162254 | CGI:chr10:125158655-125162758 | promoter | 3.94e-01 | 2.75e-01 | 1.96e+00 | 4.96e-02 | 4.96e-02 | 1.19e-01 |
| KIRP | cg05090351 | chr10:125162593 | CGI:chr10:125158655-125162758 | promoter | 8.47e-01 | 7.45e-01 | 3.44e+00 | 5.92e-04 | 2.85e-03 | 1.02e-01 |
Top |
Exon skipping events with PSI in TCGA for CTBP2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CTBP2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| LUAD | CTBP2-003 | chr10_125123132_- | 4.72e-01 | 7.31e-01 | -2.69e+00 | 7.05e-03 | 2.48e-02 | -2.60e-01 |
| COAD | CTBP2-003 | chr10_125123132_- | 3.32e-01 | 5.40e-01 | -2.51e+00 | 1.22e-02 | 2.50e-02 | -2.08e-01 |
| STAD | CTBP2-003 | chr10_125092329_- | 5.16e-01 | 4.15e-01 | 2.44e+00 | 1.49e-02 | 4.96e-02 | 1.01e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CTBP2 |
| TFs related to CTBP2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CTBP2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CTBP2 |
| RBPs related to ES in CTBP2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| STAD | SAMD4A | exon_skip_54648 | 6.91e+00 | 9.81e-01 | 6.49e+00 | 5.24e-03 | Male-biased |
| ACC | ZNF638 | exon_skip_54642 | 1.46e+01 | 3.00e-03 | 1.51e+01 | 9.97e-01 | Female-biased |
| UVM | ZNF638 | exon_skip_54642 | 1.53e+01 | 1.00e+00 | 1.47e+01 | 1.97e-04 | Male-biased |
| THYM | RBM3 | exon_skip_54640 | 1.45e+01 | 1.02e-04 | 1.53e+01 | 1.00e+00 | Female-biased |
| LUSC | ZNF638 | exon_skip_54642 | 1.45e+01 | 1.14e-03 | 1.51e+01 | 9.99e-01 | Female-biased |
| COAD | ZNF638 | exon_skip_54642 | 1.43e+01 | 4.70e-04 | 1.50e+01 | 9.99e-01 | Female-biased |
| LUAD | ZNF638 | exon_skip_54642 | 1.51e+01 | 9.99e-01 | 1.45e+01 | 1.33e-03 | Male-biased |
| BRCA | ZNF638 | exon_skip_54642 | 1.50e+01 | 9.88e-01 | 1.45e+01 | 1.17e-02 | Male-biased |
| ESCA | FXR2 | exon_skip_54640 | 7.77e+00 | 9.82e-01 | 7.32e+00 | 9.42e-03 | Male-biased |
| READ | RBM3 | exon_skip_54640 | 1.43e+01 | 7.89e-04 | 1.49e+01 | 9.99e-01 | Female-biased |
| THCA | ZNF638 | exon_skip_54642 | 1.46e+01 | 9.98e-01 | 1.42e+01 | 2.23e-03 | Male-biased |
| LGG | ZNF638 | exon_skip_54642 | 1.51e+01 | 1.00e+00 | 1.44e+01 | 3.61e-04 | Male-biased |
| PAAD | RBM3 | exon_skip_54640 | 1.46e+01 | 1.06e-03 | 1.51e+01 | 9.99e-01 | Female-biased |
| PAAD | SAMD4A | exon_skip_54648 | 6.72e+00 | 9.80e-01 | 6.35e+00 | 3.69e-03 | Male-biased |
| PAAD | ZNF638 | exon_skip_54642 | 1.42e+01 | 6.11e-05 | 1.49e+01 | 1.00e+00 | Female-biased |
| KIRC | SAMD4A | exon_skip_54648 | 6.91e+00 | 9.85e-01 | 6.37e+00 | 6.78e-04 | Male-biased |
| KIRC | ZC3H10 | exon_skip_54648 | 7.75e+00 | 9.86e-01 | 7.38e+00 | 4.51e-03 | Male-biased |
| KIRC | ZC3H10 | exon_skip_54742 | 9.39e+00 | 9.89e-01 | 9.07e+00 | 8.47e-03 | Male-biased |
| KIRC | ZNF638 | exon_skip_54642 | 1.43e+01 | 4.29e-04 | 1.50e+01 | 1.00e+00 | Female-biased |
| HNSC | ZC3H10 | exon_skip_54648 | 7.70e+00 | 9.86e-01 | 7.27e+00 | 4.06e-03 | Male-biased |
| CTBP2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7092894 | chr10:117928369:T:C | - | 0.141425944673163 | 0.0304998671141784 | PAAD | Female-baised eQTL |
| rs10885771 | chr10:115699148:T:A | - | 0.0568039954663744 | 0.0255968522176403 | LUAD | Female-baised eQTL |
| rs10736242 | chr10:115700302:G:C | - | 0.0560293476902058 | 0.0293542759385953 | LUAD | Female-baised eQTL |
| rs10885774 | chr10:115701827:T:G | - | 0.0560293476902058 | 0.0293542759385953 | LUAD | Female-baised eQTL |
| rs10885775 | chr10:115702014:T:G | - | 0.0560293476902058 | 0.0293542759385953 | LUAD | Female-baised eQTL |
| rs7067647 | chr10:115698225:A:G | - | 0.0539926101990723 | 0.0295645077479323 | LUAD | Female-baised eQTL |
| rs7897855 | chr10:115702643:G:A | - | 0.054122701732816 | 0.0343564904657139 | LUAD | Female-baised eQTL |
| rs4751561 | chr10:115694932:T:C | - | 0.0567600730266217 | 0.0346908687663725 | LUAD | Female-baised eQTL |
| rs6585351 | chr10:115697433:C:T | - | 0.0567600730266217 | 0.0346908687663725 | LUAD | Female-baised eQTL |
| rs7093582 | chr10:115691211:C:A | - | 0.054026545419821 | 0.0349159586472952 | LUAD | Female-baised eQTL |
| rs4751925 | chr10:115700555:C:G | - | 0.0560564511794194 | 0.0389787546372205 | LUAD | Female-baised eQTL |
| rs10885773 | chr10:115701668:C:T | - | 0.0560564511794194 | 0.0389787546372205 | LUAD | Female-baised eQTL |
| rs10885776 | chr10:115702073:T:C | - | 0.0560564511794194 | 0.0389787546372205 | LUAD | Female-baised eQTL |
| rs2420104 | chr10:115690123:G:C | - | 0.0558984297906009 | 0.0398958862236739 | LUAD | Female-baised eQTL |
| rs34597035 | chr10:115690561:C:T | - | 0.0558984297906009 | 0.0398958862236739 | LUAD | Female-baised eQTL |
| rs7086114 | chr10:115705168:A:G | - | 0.0533033120174355 | 0.0456156515628009 | LUAD | Female-baised eQTL |
| rs7086132 | chr10:115705201:A:G | - | 0.0533033120174355 | 0.0456156515628009 | LUAD | Female-baised eQTL |
| rs2420108 | chr10:115705779:G:A | - | 0.0533033120174355 | 0.0456156515628009 | LUAD | Female-baised eQTL |
| rs10885778 | chr10:115705978:T:C | - | 0.0531278268782998 | 0.0469274046783441 | LUAD | Female-baised eQTL |
| rs7900551 | chr10:115706532:T:C | - | 0.0531278268782998 | 0.0469274046783441 | LUAD | Female-baised eQTL |
| rs7918048 | chr10:122051091:A:G | - | -0.0722922072224121 | 0.0441059476724997 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11018251 | chr10:127662412:G:A | - | -0.054610348334973 | 0.00949855571929197 | COAD | Male-baised eQTL |
| rs11018250 | chr10:127662346:G:A | - | -0.0544685945393522 | 0.010151370557217 | COAD | Male-baised eQTL |
| rs11018260 | chr10:127673389:T:C | - | -0.0535401391556935 | 0.0125997383534294 | COAD | Male-baised eQTL |
| rs12250127 | chr10:127673812:C:T | - | -0.0535401391556935 | 0.0125997383534294 | COAD | Male-baised eQTL |
| rs2386899 | chr10:127659617:G:A | - | -0.0531010215332284 | 0.0134754755977377 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000175029 |
| CpG Site: cg11784626 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.385105070614082 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg11784626 | chr10:125093969 | gene | -0.385105070614082 | 3.74988451511935e-05 | -0.38042294435122903 | 1.4971434735686758e-07 | SKCM |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| exon_skip_54742 | chr10:125133511:125133612 | 3UTR-3UTR | rs77111523 | chr10:124973108:A:T | Distant downstream | -0.0397993973957333 | 0.0431993306233286 | KIRC | Female-baised sQTL |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CTBP2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000175029 | CTBP2 | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
| ENSG00000175029 | CTBP2 | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
| ENSG00000175029 | CTBP2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ENSG00000175029 | CTBP2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
